HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Plaintiff Claims Against Beiersdorf For ‘Unlawfully Marketed Drug’ Are Preempted By FDCA, Court Rules

Executive Summary

After five and a half years, three dismissal motions and one appeal, Beiersdorf’s prevailed on 15 April by summary judgment in a proposed class action alleging that its Nivea Skin Firming Hydration Body Lotion is an unlawfully marketed drug. Of course, the plaintiff still could appeal.

You may also be interested in...



Making Cosmetics Reform Beneficial For All; Former FDA Cosmetics Director Yearns For ‘Serious Sit-Down’

Federal legislative reform is an historic opportunity not only to strengthen the US FDA’s oversight of the cosmetics sector, but also to modernize the industry and its value proposition to consumers. John Bailey, independent advisor for cosmetics and colors at EAS Consulting Group, is confident there’s a way to do all, but "serious" stakeholder negotiations are needed.

Cosmetics Industry Stakeholders Not Thrilled About Senate Reform Bill, And Why Should They Be?

In HBW Insight’s conversations with industry advocates about legislation in the US Senate to reform US cosmetics regulations, frustrations with the process have been palpable. Stakeholders suggest that science and proportionality are taking back seats to politics and that concerns about costs to industry, which ultimately could be passed on to consumers, are not being taken seriously enough.

CBD Class-Action Litigants Watching For Retroactive Effects In US FDA’s Awaited Rulemaking

Even in the “highly unlikely event” that the FDA does make CBD supplements legal, it will not do so retroactively, according to plaintiffs against CV Sciences in California’s Central District. However, the federal court, which also is hearing a similar case against competitor Charlotte’s Web, is not convinced.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS149949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel